Nephrology therapy concern Akebia Therapeutics, Inc. is down ~65% from its 2014 IPO price of $17 even with a recent rally.
Two critical Phase 3 readouts are due in mid-2020 that should pave the way for FDA approval of its erythropoiesis asset (vadadustat) with blockbuster potential.
However, competition from two similar candidates is looming.
Insider buying in late November triggered a one-day 22% gain.
A full investment analysis follows in the paragraphs below.
Historian -- an unsuccessful novelist." - H.L. Mencken
Today, we take a deeper look at a small biotech concern that has been very volatile in its history as a public company. However, it has